Pharming Group N.V. revenue breakdown overview

Pharming Group N.V. revenue for the last year amounted to 297.20 M USD, the most of which — 297.20 M USD — came from its highest performing source at the moment, Recombinant Human C1 Esterase Inhibitor, the year earlier bringing 245.32 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Pharming Group N.V. 287.15 M USD, and the year before that — 239.11 M USD.